drugset / Trial / NCT00783198

Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)

NCT00783198

Phase 2/3 Completed 565 enrolled ALK-Abelló A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period. It is expected that ragweed allergic participants on one of the active arms of the trial will have decreased allergic rhinoconjunctivitis symptoms and require less allergy rescue medications during ragweed pollen season.

Timeline

Start
2009-09
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject SCH 39641 Unknown 6 unknown Other
Subject SCH 39641 Unknown 12 unknown Other